Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Bone Density Conservation Agents
Prostatic Neoplasms, Castration-Resistant
Steroid Synthesis Inhibitors
Treatment patterns for advanced prostate cancer have changed substantially in the last few years. This additional analysis provides evidence of clinical benefit for subsequent chemotherapy in men with advanced prostate cancer whose disease progressed after treatment with abiraterone acetate. Older patients were less likely to be treated with subsequent therapy.